Pharmaceutical Technology Integration
Most commercial technology problems in pharma are not tool problems. The licences are usually already bought. The failure is that the CRM does not know what marketing sent, the content system does not know what was approved for which market, and consent lives in three places that disagree.
In short
Hibridge implements and connects the commercial technology stack pharmaceutical companies run on — CRM, closed-loop marketing, content and digital asset management, marketing automation, consent and preference management, and event platforms — so that field activity, digital engagement and approved content operate on one dataset instead of several.
What we do
Making the CRM, the content stack and the field actually connect.
CRM and closed-loop marketing
Implementation, migration and remediation on the platforms regional commercial teams actually run, with field adoption treated as part of the scope rather than an afterthought.
Content and DAM
Approved-asset repositories with market, language and expiry metadata, so reuse is safe and traceable.
Marketing automation
Journey orchestration wired to CRM activity, so digital timing responds to field activity instead of ignoring it.
Consent and preference management
A single consent record per HCP across channels and markets, built against local data protection law including Egypt’s PDPL.
Event and engagement platforms
Registration, virtual delivery and engagement capture, integrated so event data lands in CRM rather than a spreadsheet.
Integration and data flow
The connective work between systems, with a documented data model and defined ownership for every field.
Approach
How an integration runs
01
Map
Current systems, actual data flows, and where records diverge. Usually the first honest map the organisation has had.
02
Design
Target data model, system of record per entity, and consent architecture agreed before configuration.
03
Implement
Phased delivery with validation at each stage and no big-bang cutover.
04
Adopt
Training, field enablement and a usage baseline, because an unadopted system is an unmeasured one.
Why it matters
Synchronised engagement measurably outperforms unsynchronised engagement. Synchronisation is a data problem before it is a marketing one.
65%
Veeva Systems (Veeva Pulse Field Trends Report) ·
23%
Veeva Systems (Crossix + CRM data, 230+ US brands) ·
Sources
Every figure on this page is attributed to its original publisher. Where a figure is organiser-reported or secondary, we say so.
Frequently asked questions
- Are you tied to a particular vendor?
- No. We work across the platforms regional commercial teams run and have no reseller relationship with any of them. Where a licence is already in place, the usual recommendation is to make it work rather than replace it.
- How do you handle data protection?
- Egypt’s Personal Data Protection Law and the relevant GCC frameworks are treated as design constraints from the mapping stage, alongside GDPR where an EU parent is in scope. Consent architecture is decided before configuration, not retrofitted.
- Can you work with our global IT function?
- Yes, and typically we have to. Most engagements involve a global template that must be extended for local requirements without breaching global governance.
Related services
Conference & Event Management
Congresses, symposia and advisory boards, run to pharma standards.
Conferences & EventsGo-To-Market & Product Launch
Launch sequencing built around what the market will actually reimburse.
Go-To-MarketPharmaceutical Marketing
HCP and patient programmes that survive review and move prescribing.
MarketingTell us what you are working on.
A launch, a congress, a portfolio that is not performing, or a compliance process that has become the bottleneck. We reply within one business day.